SCHEMBL21992007

SCHEMBL21992007

CC(COc1ccc(Oc2ccc(Cl)cc2)cc1)C(C)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 8/20 0.51
PPARG P37231 7/20 0.51
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 2/20 0.46
RAB9A P51151 1/20 0.46
CYP1A2 P05177 2/20 0.46
ACACB O00763 1/20 0.43
ACACA Q13085 1/20 0.43
SCN4A P35499 2/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C19 P33261 1/20 0.41
P2RX3 P56373 1/20 0.41
NR4A2 P43354 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21991335 0.95 PPARA (0.55) PPARAPPARGMEN1KMT2AALDH1A1
SCHEMBL21992005 0.88 HPGD (0.51) PPARAPPARGMEN1KMT2AALDH1A1
SCHEMBL21992009 0.87 NR4A2 (0.58) PPARAPPARGMEN1KMT2ARAB9A
SCHEMBL21991993 0.85 CYP1A2 (0.47) PPARAPPARGMEN1KMT2AALDH1A1
SCHEMBL11536518 0.84 PPARA (0.54) PPARAPPARGMEN1KMT2AALDH1A1
SCHEMBL21991942 0.84 CYP1A2 (0.46) PPARAPPARGMEN1KMT2AALDH1A1
SCHEMBL21992727 0.84 CYP1A2 (0.46) PPARAPPARGMEN1KMT2AALDH1A1
SCHEMBL21991593 0.83 L3MBTL1 (0.52) PPARAPPARGMEN1KMT2ARAB9A
SCHEMBL21991962 0.81 MEN1 (0.46) PPARAPPARGMEN1KMT2AALDH1A1
SCHEMBL21991932 0.81 LDHA (0.50) PPARAPPARGKMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220409566-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-12-29 US disclosed
US-20220142961-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-05-12 US disclosed
US-11318111-B2 CCL5 inhibitors LAPKO INC (US) 2022-05-03 US disclosed
US-20210196665-A1 CCL5 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-07-01 US disclosed
US-10940132-B2 CCL5 inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-03-09 US disclosed
US-20200138766-A1 CCL5 INHIBITORS LAPKO INC. DBA AFECTA PHARMACEUTICALS 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142961-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 PPARA 806/4885PPARG 1583/4885MEN1 3749/4885
US-20200138766-A1 CCL5 INHIBITORS CCL5, CCL11, CCR5 PPARA 806/4885PPARG 1583/4885MEN1 3749/4885
US-20210196665-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 PPARA 806/4885PPARG 1583/4885MEN1 3749/4885
US-10940132-B2 CCL5 inhibitors CCL5, CCL11, CCR5 PPARA 806/4885PPARG 1583/4885MEN1 3749/4885
US-11318111-B2 CCL5 inhibitors CCL5, CCL11, CCR5 PPARA 806/4885PPARG 1583/4885MEN1 3749/4885
US-20220409566-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 PPARA 806/4885PPARG 1583/4885MEN1 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.